The tumor marker S100B represents a novel MM target since it is elevated in >90% of patients, it correlates directly with poor survival [38, 39], contributes to the degradation of wild type p53 tumor suppressor [9–12, 40–56] and may contribute to immune evasion, particularly as recognized in melanoma vaccine clinical trials [2, 39, 57, 58]. Here, TP53 is linked to Miyoshi myopathy.